During trading on Thursday, traders have sold shares of Gilead Sciences on strength. As per traders, $282.09 million flowed into the stock on the tick-up and $412.41 million flowed out of the stock on the tick-down. Gilead Sciences was the sixth highest net-out-of-flow for the day.

Lately, Gilead Sciences has been the subject of many research reports. Morgan Stanley has reiterated an “overweight” rating on shares of the company. Deutsche Bank has also reissued a ‘buy’ rating and has set $125.00 target price on shares of the company.

Bank of America has given underperform rating on shares of Gilead Sciences. On the other hand, Vetr has raised shares of the company to a strong buy and has set a $129.06 target price on the stock. Argus has set a $150.00 price target on the company’s shares.

To talk about analysts then one has rated the stock with a sell rating and four have issued a hold rating and 21 have given a buy rating and two have given a strong buy rating. Experts said that the stock is having market cap of $158.49 billion and a PE ratio of 11.40.

The company has posted its quarterly earnings data on July 28. The company has topped the consensus estimate. For the quarter, the company has report revenue of $8.22 billion in comparison to the consensus estimate of $7.60 billion. In comparison to the same quarter last year, the company’s revenue was up 25.8%.